Clinical trials: Overweight
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Obesity or Overweight
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult…
- Trial name
- NCT07081958
- Testing
- RO7795081
- Where
- 36 sites in United States
- Volunteers
- 352 people
- Sponsor
- Hoffmann-La Roche
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Overweight, Obesity
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite…
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Trial name
- NCT07895563
- Testing
- MN Nutra GeLiPthin-1™ Dietary Supplement
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- MNnutra
Overweight or Obesity Without Diabetes
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight…
- Trial name
- RISE-1 (NCT07896265)
- Testing
- Olatorepatide
- Volunteers
- 3,000 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight and Obesity
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its…
- Trial name
- CONTEMPO (NCT06151964)
- Testing
- AZD9550, AZD9550 and AZD6234
- Where
- 15 sites in Austria, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Overweight or Obesity
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
This study aims to evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.
- Trial name
- NCT05881837
- Testing
- HRS9531 injection
- Where
- 25 sites in China
- Volunteers
- 249 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight, Obesity
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks.
- Conditions
- Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression
- Trial name
- NCT07889570
- Testing
- Evolv GLP-1 Group, Control Group
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Evolv
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.
- Trial name
- NCT07890870
- Testing
- IBIO-610
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity, Overweight
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation…
- Trial name
- NCT07280936
- Testing
- SHR-2906 Injection
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Overweight , Obesity
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal…
- Trial name
- NCT07443059
- Testing
- Zovaglutide
- Where
- 3 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight,Obesity
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin…
- Trial name
- NCT07550816
- Testing
- ZT002 injection, metformin, warfarin, ZT002 injection, rosuvastatin, digoxin
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight, Obesity
A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults
This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.
- Trial name
- NCT07697846
- Testing
- ZT002 injection
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics